Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Towse at ISPOR: Macro HTA and Managed Entry Agreements
7 October 2014
Adrian Towse, currently President of ISPOR, contributed to two session at the recent ISPOR Asia-Pacific conference. Using HTA to maximise health system performance: Health technology assessment…
Bengt Jönsson Honoured for Contribution to Health Economics
6 August 2014
Launched at a seminar in his honour May 2014, Portrait of a Health Economist: Essays by Colleagues and Friends of Bengt Jönsson is an impressive collection…
Spotlight on OHE: NICE, Biosimilars, HTA
17 June 2014
OHE’s active involvement in a number of recent conferences and meetings has contributed to discussions on a range of important issue in health economics.
Implementing NICE Decisions in Wales: Opportunity Costs
10 June 2014
Just out is a new Research Paper from OHE that examines how local NHS organisations in Wales adjust spending to accommodate ‘shocks’ such as new NICE…
OHE’s Adrian Towse to Take Office as ISPOR President
3 June 2014
The challenge of globalisation heads Towse’s list of four core targets for ISPOR. OHE’s Director, Adrian Towse, is President of the International Society for Pharmacoeconomics and…
Orphan Drugs Policies: A Suitable Case for Treatment
20 May 2014
Towse and Drummond take a critical look at deficiencies in policy and suggest revisions. An editorial just published by OHE’s Adrian Towse and Michael Drummond of…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
A new OHE Consulting Report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. The potential value…
How Will Demands for Effectiveness Evidence Change Drug Development?
23 April 2014
Interviews with 19 senior pharma execs suggest how and to what extent effectiveness research may be integrated into drug development. Changes in the clinical and economic…
Biosimilars and HTA: Results of a Roundtable Discussion
9 April 2014
Experts from the three UK HTA agencies, the MHRA, and academia discussed which HTA methods are most appropriate for biosimilars in specific situations. OHE convened a…